Inlyta data fails to convince NICE

 Pfizer’s treatment of advanced kidney cancer Inlyta (axitinib) has not been recommended in draft guidance.

NICE’s independent Appraisal Committee questioned the trial data supplied by Pfizer and were left concerned about the drug’s validity and reliability.

Sir Andrew Dillon, NICE Chief Executive, said the Institute will not “divert NHS funds to a treatment that costs more but doesn’t help people live longer.”

The appraisal considered the use of Inlyta for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine.

However, experts told the Appraisal Committee that the use of cytokines in clinical practice is declining with only a handful of patients currently using the treatments. NICE was informed that the majority of patients are now being treated with sunitinib or pazopanib – both recommended by NICE.

Pfizer supplied NICE with trial data comparing Inlyta to sofafenib, a drug not recommended by NICE and not identified in the scope. “The trial also lacked a comparison to ‘best supportive care’, which is what the majority of patients receive at the moment; therefore an ‘indirect’ and ‘simulated’ comparison was made using separate data from another trial,” Sir Andrew Dillon said.

The recommendation is now open for consultation. Pfizer has also been invited to comment on the evidence it supplied as part of the appraisal.